International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (410-415), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Pathogenesis and treatment approaches of Graves Ophthalmopathy: Systematic review

[1]Yasir wadi alanazi, [2]Bassam wadi alanazi, [3]Rawan wadi alenazi,
[4]Raed khalid raja alanazi

Abstract: **Graves' ophthalmopathy (GO), or more accurately thyroidassociated ophthalmopathy, is a typical reason for morbidity and pain in patients with Graves' disease. Around 20-25% of patients with Graves' hyperthyroidism have medically evident GO at the time of diagnosis. We conducted our systematic review study by searching electronic database such as PubMed ,Cochrane Library for the term: Graves ophthalmopathy or Graves orbitopathy, pathogensis and similar, crossed with specific treatment regimens and Cochrane highly sensitive search strategy for RCTs and reviews. We scanned references of all included trials and reviews identified for additional studies. Study selection We included all RCTs comparing treatment modalities for GO with placebo, no-intervention, or other treatment modalities. Existing proof shows the effectiveness of iv corticosteroids in reducing CAS in patients with moderate to serious GO. Intravenous pulse corticosteroids have a statistically substantial however small benefit compared to oral corticosteroids and triggers substantially less negative occasions. This treatment is restricted by expense and threat for unusual extreme unfavorable occasions.**

Keywords: **Graves Ophthalmopathy, Pathogenesis.**

1. INTRODUCTION

Graves' ophthalmopathy (GO), or more accurately thyroidassociated ophthalmopathy, is a typical reason for morbidity and pain in patients with Graves' disease. Around 20-25% of patients with Graves' hyperthyroidism have medically evident GO at the time of diagnosis [(1)]. A lot more patients have proof of ophthalmopathy on ultrasonography, calculated tomography, or magnetic resonance imaging of the orbits [(2,3)]. GO might lead to eyelid retraction, proptosis, chemosis, periorbital edema, and transformed ocular motility. Serious GO causes direct exposure keratopathy, diplopia, and compressive optic neuropathy, which may trigger visual loss [(3)].

The scientific symptoms of GO come from a mix of increased orbital fat and extraocular muscle volume within the orbital area, due to the fact that the bony orbit does not have compliance, anterior displacement of the consisted of tissues might result, causing proptosis, or protrusion of the world. The increased orbital pressure likewise triggers problems of lymphatic and venous outflow and congestive swelling of the periorbital tissues [(4)]. Orbital adipose tissue volume growth predominates in some patients and increased extraocular muscle volume is popular in others, the majority of patients reveal a mix of both procedures (***Figure. 1***).

The management of moderate to serious GO is difficult, needing a multidisciplinary group of both eye doctors and endocrinologists, one study of physicians who deal with patients with GO released in 2006 reported that suboptimal management of these patients is extensive [(5)]. A just recently released agreement declaration by the European Group on GO (EUGOGO) [(6, 7)], intending to enhance result of patients with GO, highlighted the requirement for an evidence-based method in dealing with these patients.



Figure.1: Computerized tomographic scan of the orbits of a patient with Graves' ophthalmopathy showing enlargement of both the orbital fat and the extraocular muscles. The expanded orbital tissues cause forward displacement of the globe and impairment of venous and lymphatic outflow from the orbit.

In GO, the particular histologic modifications within the orbital tissues laid out above recommend that the orbital fibroblast makes up the target cell. Rather than being an uniform population of cells, the fibroblasts show amazing phenotypic heterogeneity [8]. One sub-population of these cells can produce hyaluronic acid and inflammatory prostanoids; other cells (described "preadipocyte fibroblasts" or "preadipocytes") can separate into fully grown adipocytes. The previous subpopulation is discovered in connective tissues investing the extraocular muscles, and the latter, the preadipocytes, is discovered mostly in the orbital fat compartment. These phenotypic distinctions in between fibroblasts within the orbit might assist to discuss why some patients with GO have primary eye muscle disease (albeit with periodic proof of fat build-up within the muscles). and others have expansion of the adipose tissue compartment as the major disease feature [8].

2. METHODOLOGY

We conducted our systematic review study by searching electronic database such as PubMed ,Cochrane Library for the term: Graves ophthalmopathy or Graves orbitopathy, pathogensis and similar, crossed with specific treatment regimens and Cochrane highly sensitive search strategy for RCTs and reviews. We scanned references of all included trials and reviews identified for additional studies. Study selection We included all RCTs comparing treatment modalities for GO with placebo, no-intervention, or other treatment modalities. We included trials regardless of publication status and language. We did not include studies evaluating treatments for Graves' disease in which ophthalmopathy was a not in concerned and did not include studies evaluating modalities aimed at alleviating selective complications of GO such as diplopia or exophthalmos. different reviewers independently inspected the references identified by the search and applied inclusion criteria. For possibly relevant articles or in cases of disagreement between the two reviewers, we obtained and independently inspected the full article.

3. RESULTS AND DISCUSSION

Pathogenesis of GO:

Graves' disease (GD) is an autoimmune condition defined by overproduction of thyroid hormones due to unregulated stimulation of the thyroid by circulating TSH receptor antibodies. We have identified and included several studies [9-23] that showed that the close clinical association between onset of Medical research studies reveal that GO occurrence is increased in GD patients having the greatest levels of TRAbs, and that euthyroid patients with GO usually have raised

TRAb levels [9,10]. Even more supporting proof linking TSHr obtains from connections in between TSHr expression in GO tissues and the activity or intensity of the disease; TSHr mRNA levels are greater in orbital adipose tissue of GO patients than in orbital tissue from patients without eye disease [16]. These research studies recommend that de novo adipogenesis is boosted in the orbits of GO patients, and that the boost in levels of TSHr expression seen in GO orbital tissues is a repercussion of this procedure.

Graves's hyperthyroidism and the advancement of GO recommends that these 2 conditions might share pathogenic systems, since autoantibodies directed versus TSHr [TSHr autoantibodies (TRAbs)] are understood to be accountable for the hyperthyroidism of GD, detectives have actually long looked for proof that TRAbs may be included too in GO pathogenesis. Scientific research studies reveal that GO occurrence is increased in GD patients having the greatest levels of TRAbs, which euthyroid patients with GO typically have raised TRAb levels [9,10]. The scientific activity rating, a composite based on indications of inflammation such as orbital pain, conjunctival erythema, and chemosis, is associated with levels of both TSHr tsh-binding and stimulatory repressive TRAbs; a weaker, however likewise considerable, connection was discovered in between levels of these antibodies and proptosis [11]. In a big longitudinal research study, TSH-binding repressive antibody levels were considerably greater in patients with extreme disease than in patients with moderate GO [12].

A requirement for the participation of TSHr and TRAbs in GO would appear to be that the TSHr is revealed in impacted orbital tissue. This has actually been convincingly displayed in a number of research studies showing both TSHr mRNA and protein in orbital fibroblasts from regular people and patients with GO [13,14,15]. Even more supporting proof linking TSHr stems from connections in between TSHr expression in GO tissues and the activity or intensity of the disease; TSHr mRNA levels are greater in orbital fat of GO patients than in orbital tissue from patients without eye disease [16]. These findings recommend that increased TSHr expression might either be straight associated with the advancement of GO, or secondary to its advancement. Even more, orbital tissues from patients with active GO have considerably greater levels of TSHr expression than do tissues from patients with non-active disease [17]. Research studies recommend that extrathyroidal TSHr is practical and displays homes much like those of the thyroidal receptor; TSH stimulation of TSHr in human stomach preadipocytes and orbital fibroblasts causes activation of p70 S6 kinase (p70 S6K), an enzyme acknowledged as a downstream target of TSHr in thyroid cells [18]. In addition, the treatment of both typical and GO orbital fibroblast cultures with TSH leads to increased cyclic adenosine monophosphate (AMP) production [19]. This is most noticable in cultures subjected to conditions that prefer adipocyte distinction, recommending that fully grown fat cells reveal TSHr to a higher degree than do preadipocyte fibroblasts.

Orbital preadipocyte fibroblast cultures treated with the PPAR-γ agonist rosiglitazone, or cultured under adipogenic other conditions, go through significant adipogenesis and reveal increased expression of TSHr and adipocyte-associated genes, consisting of PPAR-γ, leptin, and adiponectin [20,21]. Specimens of orbital adipose tissue from GO patients over-express PPAR-γ, tshr, adiponectin, and leptin compared with regular orbital adipose tissue [22,23]. These research studies recommend that de novo adipogenesis is boosted in the orbits of GO patients, which the boost in levels of TSHr expression seen in GO orbital tissues is an effect of this procedure. Research studies from our lab have actually revealed that monoclonal TRAbs are powerful stimulators of adipogenesis in cultures of GO and typical orbital preadipocyte fibroblasts [23].

Treatment approaches of GO:

- **Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy:**

Radioactive iodine (RAI) treatment is a commonly pre-owned and reliable treatment for Graves' hyperthyroidism, together with antithyroid drugs and surgery. Its usage is restricted by the possible danger of advancement or worsening of Graves' ophthalmopathy (GO) following treatment. While a number of reports did not show development of GO following RAI [24,25].

We have actually consisted of an organized evaluation research study [26] that intended to evaluate whether RAI for GD is connected with increased danger of ophthalmopathy compared to antithyroid drugs (ATDs) or surgery and this research study invloved Six RCTs methodically assessed eye results after RAI with ophthalmopathy as a primary result. Quality of ophthalmopathy description was heterogeneous in these trials. 4 trials examined ophthalmopathy as a secondary result without pointing out the approach utilized however explained the eye result such as serious ophthalmopathy needing immunosuppression. RAI vs. ATD. 2 RCTs compared RAI with ATD. Ophthalmopathy established in 36 from 189

patients who got RAI compared to 8 from 186 patients who got ATD. RAI treatment was related to increased threat of developing or worsening ophthalmopathy compared with ATD (RR 4·23; 95% CI 2·04–8·77) [26].

- **Glucocorticoid for Prevention of Graves' Ophthalmopathy Progression Following Radioiodine Treatment:**

Glucocorticoid (GC) therapy has been revealed to avoid Graves' ophthalmopathy (GO) development following radioactive iodine (RAI) treatment. The ideal routine is questionable, with research studies from current years recommending the usage of lower dosages and much shorter GC treatment courses. The effectiveness of corticosteroids in avoidance of RAI caused GO activation was well shown in 2 randomized regulated trials (RCTs) by Bartalena et al., utilizing prednisone tapered over 3 months [27,29]. Ever since, a number of research studies examined lower dosages of prednisone with much shorter treatment period [30], and some research studies discovered steroid prophylaxis to be inefficient [28,12]. Inning accordance with a treatment agreement of the European Group on Graves' Orbitopathy (EUGOGO) released in 2008, and the management standards of the American Thyroid Association (ATA) in association with the American Association of Clinical Endocrinologists (AACE), prednisone prophylaxis 0.4-0.5 mg/kg is suggested in patients acknowledged to be at threat for GO activation, tapered over 3 months [6,31].

Meta-analysis and systematic review study [32] was identified and included in our review comparing ***Glucocorticoid*** regimens versus placebo, no treatment, for patients with preexisting GO, they found GO progression in patients with preexisting GO, however not in patients without preexisting eye participation. The most validated routine is prednisone 0.4-0.5 mg/kg offered for 3 months or more in patients with pre-existing eye disease, as suggested by both the ATA/ACEE management standards from 2011 and the EUGOGO agreement declaration from 2008[32]. While this program was examined in patients with moderate or moderate GO, more recent research studies assessed low-dose prednisone (0.2-0.3 mg/kg for 4 to 6 weeks) in patients with moderate GO or threat aspects, which was discovered to be a reliable option with considerably less unfavorable impacts. In patients without preexisting GO, steroid prophylaxis was inadequate in avoiding GO advancement. In patients without preexisting GO, basic dosage prednisone (0.4-0.5 mg/kg for 3 months) was assessed in 2 RCTs and 2 retrospective research studies, and was inefficient (OR 1.87 [CI 0.81- 4.3]. Betamethasone was assessed in 2 RCTs, and was likewise discovered to be inadequate (OR 6 [CI 0.68– 52.9]) [32].

- **Comparison of different treatments:**

We included large Systematic review study [34] that analyzed 8 studies involving 1402 patients from 5 continents, Qualified research studies were randomized scientific trials and relative friend research studies in grownups that consisted of 2 or more treatment alternatives for GO. Comparing in between antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy, they have actually discovered Clinical experience shows that 2 techniques effectively get rid of hyperthyroidism. The relative efficiency of these treatments, as defined by regression rates, is shown in the literature just by low-grade proof. As anticipated, they discovered ATDs to have a greater regression rate than either RAI treatment or thyroidectomy, with the latter 2 treatments having no considerable distinction in regression rates. It is necessary to keep in mind that the most "reliable" treatment from the doctor's point of view both gets rid of hyperthyroidism and avoids its reoccurrence. The objective of both RAI and thyroidectomy is to render the patient hypothyroid such that long-lasting thyroid hormonal agent replacement is essential. On the other hand, patients might well want a treatment that has the possible to permit their thyroid to resume typical performance. In this sense, ATDs bring a benefit over surgery and RAI that was not caught in our relative efficiency information. The mean dosage of RAI was 8.5 mCi (variety, 6.8 to 12.6) [34]. Dosing was generally based upon goiter size and RAI uptake. In addition, one research study included age, gender, and scientific intensity in dosage decisions, whereas in another, dosing was empirical. The fairly low dosages of RAI utilized in these research studies might be described by the addition of patients from iodine-deficient nations that have the tendency to have greater RAI uptake, by guidance provided to some patients to follow a low-iodine diet plan prior to RAI treatment or by the objective of RAI in some practices being to accomplish euthyroidism instead of to render the patient hypothyroid as recommended in recent guidelines [33].

4. CONCLUSION

Existing proof shows the effectiveness of iv corticosteroids in reducing CAS in patients with moderate to serious GO. Intravenous pulse corticosteroids have a statistically substantial however small benefit compared to oral corticosteroids and triggers substantially less negative occasions. This treatment is restricted by expense and threat for unusual extreme unfavorable occasions. Viewpoint is divided among endocrinologists on whether RAI is related to GO and our methodical evaluation validates RAI for GD is related to a small however absolutely increased danger of event or development of GO compared to ATD/surgery

REFERENCES

[1] Burch HB, Wartofsky L 1993 Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14:747–793.

[2] VilladolidMC, Yokoyama N, IzumiM, Nishikawa T, Kimura H, Ashizawa K, Kiriyama T, Uetani M, Nagataki S 1995 Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830 –2833.

[3] Werner SC, Coleman DJ, Franzen LA 1974 Ultrasonographic evidence of a consistent orbital involvement in Graves' disease. N Engl J Med 290:1447– 1450.

[4] Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142:147–153.

[5] Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Mourits MP, Nardi M, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Wiersinga WM 2006 A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur J Endocrinol 155:207–211.

[6] Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C,MouritsMP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18:333–346

[7] Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285

[8] Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385–392.

[9] Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT, Aw SE. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000;10:1093–1100.

[10] Khoo DH, Ho SC, Seah LL, Fong KS, Tai ES, Chee SP, Eng PH, Aw SE, Fok AC. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid. 1999;9:1175–1180.

[11] Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol.2000;52:267–271.

[12] Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab.2006;91:3464–3470.

[13] Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet. 1993;342:337–338.

[14] Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid.1993;3:297–300.

[15] Starkey K, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases *ex vivo* and indicates adipogenesis in progress *in vivo*. J Mol Endocrinol. 2003;30:369–380.

[16] Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1998;83:998–1002.

[17] Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol.2003;58:280–287.

[18] Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ, Sorisky A. Functional TSH receptor in human abdominal pre-adipocytes and orbital fibroblasts. American Journal of Physiology: Cell Physiol.2000;279:C335–C340.

[19] Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, Bahn RS. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab. 1999;84:2557–2562.

[20] Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital pre-adipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352–2358.

[21] Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004;89:930–935.

[22] Kumar S, Leontovich A, Coenen MJ, Bahn RS. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab. 2005;90:4730–4735.

[23] Stan MN, Coenen MJ, Bahn RS. Adipogenesis is stimulated by thyrotropin receptor autoantibodies and TSH in Graves' orbital preadipocytes. Thyroid. 2006;16:859–860.

[24] Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR 2008 Radioiodine therapy and Graves' ophthalmopathy. J Nucl Med 49:923–930.

[25] Sridama V, DeGroot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87:70–73.

[26] Shamasunder H. Acharya, Alison Avenell, Sam Philip, Jennifer Burr†, John S. Bevan and Prakash Abraham. ckwell Publishing Ltd Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clinical Endocrinology (2008) 69, 943–950.

[27] Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73–78.

[28] Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M 2009 Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94:3381–3386.

[29] Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A 1989 Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321:1349–1352.

[30] Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333–1337.

[31] Jensen BE, Bonnema SJ, Hegedus L 2005 Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease. Eur J Endocrinol 153:15–21.

[32] Shachaf Shiber, Hadas Stiebel-Kalish, Ilan Shimon, Alon Grossman, and Eyal Robenshtok. Glucocorticoid Regimens for Prevention of Graves' Ophthalmopathy Progression Following Radioiodine Treatment: Systematic Review and Meta-Analysis. DOI: 10.1089/thy.2014.0218

[33] Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17:456–520.

[34] Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves' hyperthyroidism: A systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98:3671–7.